chrX-120447921-C-T

Variant summary

Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2

The NM_002294.3(LAMP2):​c.661G>A​(p.Gly221Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00221 in 1,209,052 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 848 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0019 ( 0 hom., 62 hem., cov: 23)
Exomes 𝑓: 0.0022 ( 0 hom. 786 hem. )

Consequence

LAMP2
NM_002294.3 missense

Scores

5
8
4

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:17

Conservation

PhyloP100: 3.07
Variant links:
Genes affected
LAMP2 (HGNC:6501): (lysosomal associated membrane protein 2) The protein encoded by this gene is a member of a family of membrane glycoproteins. This glycoprotein provides selectins with carbohydrate ligands. It may play a role in tumor cell metastasis. It may also function in the protection, maintenance, and adhesion of the lysosome. Alternative splicing of this gene results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.02191636).
BP6
Variant X-120447921-C-T is Benign according to our data. Variant chrX-120447921-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 44434.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=5, Benign=6, Uncertain_significance=1}. Variant chrX-120447921-C-T is described in Lovd as [Pathogenic]. Variant chrX-120447921-C-T is described in Lovd as [Benign]. Variant chrX-120447921-C-T is described in Lovd as [Likely_benign].
BS2
High Hemizygotes in GnomAd4 at 62 XL gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
LAMP2NM_002294.3 linkc.661G>A p.Gly221Arg missense_variant Exon 5 of 9 ENST00000200639.9 NP_002285.1 P13473-1
LAMP2NM_001122606.1 linkc.661G>A p.Gly221Arg missense_variant Exon 5 of 9 NP_001116078.1 P13473-3
LAMP2NM_013995.2 linkc.661G>A p.Gly221Arg missense_variant Exon 5 of 9 NP_054701.1 P13473-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
LAMP2ENST00000200639.9 linkc.661G>A p.Gly221Arg missense_variant Exon 5 of 9 1 NM_002294.3 ENSP00000200639.4 P13473-1

Frequencies

GnomAD3 genomes
AF:
0.00188
AC:
210
AN:
111755
Hom.:
0
Cov.:
23
AF XY:
0.00183
AC XY:
62
AN XY:
33915
show subpopulations
Gnomad AFR
AF:
0.000390
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00495
Gnomad ASJ
AF:
0.00453
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.000999
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00231
Gnomad OTH
AF:
0.00334
GnomAD3 exomes
AF:
0.00155
AC:
285
AN:
183483
Hom.:
1
AF XY:
0.00131
AC XY:
89
AN XY:
67921
show subpopulations
Gnomad AFR exome
AF:
0.000608
Gnomad AMR exome
AF:
0.00175
Gnomad ASJ exome
AF:
0.00267
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00137
Gnomad NFE exome
AF:
0.00208
Gnomad OTH exome
AF:
0.00375
GnomAD4 exome
AF:
0.00224
AC:
2463
AN:
1097247
Hom.:
0
Cov.:
30
AF XY:
0.00217
AC XY:
786
AN XY:
362617
show subpopulations
Gnomad4 AFR exome
AF:
0.000152
Gnomad4 AMR exome
AF:
0.00230
Gnomad4 ASJ exome
AF:
0.00268
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000185
Gnomad4 FIN exome
AF:
0.00118
Gnomad4 NFE exome
AF:
0.00261
Gnomad4 OTH exome
AF:
0.00180
GnomAD4 genome
AF:
0.00188
AC:
210
AN:
111805
Hom.:
0
Cov.:
23
AF XY:
0.00182
AC XY:
62
AN XY:
33975
show subpopulations
Gnomad4 AFR
AF:
0.000389
Gnomad4 AMR
AF:
0.00494
Gnomad4 ASJ
AF:
0.00453
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.000999
Gnomad4 NFE
AF:
0.00231
Gnomad4 OTH
AF:
0.00330
Alfa
AF:
0.00241
Hom.:
107
Bravo
AF:
0.00214
TwinsUK
AF:
0.00216
AC:
8
ALSPAC
AF:
0.00312
AC:
9
ESP6500AA
AF:
0.00104
AC:
4
ESP6500EA
AF:
0.00253
AC:
17
ExAC
AF:
0.00123
AC:
149
EpiCase
AF:
0.00169
EpiControl
AF:
0.00237

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:17
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Benign:5
May 26, 2015
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

p.Gly221Arg in LAMP2: This variant is not expected to have clinical significance because it has been identified in 0.2% (84/47999) of European chromosomes, incl uding 30 males, by the Exome Aggregation Consortium (ExAC, http://exac.broadins titute.org/; dbSNP rs145169006). -

Mar 04, 2019
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: LAMP2 c.661G>A (p.Gly221Arg) results in a non-conservative amino acid change in the encoded protein sequence. Three of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0015 in 200310 control chromosomes in the gnomAD database, including 1 homozygote and 95 hemizygotes. The observed variant frequency is approximately 120 fold of the estimated maximal expected allele frequency for a pathogenic variant in LAMP2 causing Cardiomyopathy phenotype (1.3e-05), strongly suggesting that the variant is benign. The variant c.661G>A has been reported in the literature in patients with dilated (DCM) or hypertrophic (HCM) cardiomyopathies, however without evidence for causality (e.g. Mook 2013, Cecconi 2016, Mademont-Soler 2017). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign (2x)/likely benign(4x). Based on the evidence outlined above, the variant was classified as benign. -

-
Clinical Genetics, Academic Medical Center
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Oct 31, 2016
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Danon disease Benign:5
-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 28, 2019
Mendelics
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 28, 2017
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. -

Aug 08, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:4
-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Sep 24, 2020
GeneDx
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is associated with the following publications: (PMID: 25091525, 23785128, 28074886, 27600940) -

Cardiomyopathy Benign:2
May 14, 2019
Center for Advanced Laboratory Medicine, UC San Diego Health, University of California San Diego
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 21, 2023
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Intellectual disability Uncertain:1
Apr 07, 2020
Human Genetics Laboratory, State University of Rio de Janeiro
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: research

- -

Cardiovascular phenotype Benign:1
Jun 15, 2017
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.66
BayesDel_addAF
Benign
-0.26
T
BayesDel_noAF
Benign
-0.15
CADD
Benign
23
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.49
.;T;.
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.90
D;D;D
M_CAP
Pathogenic
0.88
D
MetaRNN
Benign
0.022
T;T;T
MetaSVM
Uncertain
-0.24
T
MutationAssessor
Pathogenic
3.2
M;M;M
PrimateAI
Uncertain
0.49
T
PROVEAN
Pathogenic
-5.4
D;D;D
REVEL
Uncertain
0.41
Sift
Pathogenic
0.0
D;D;D
Sift4G
Uncertain
0.0030
D;D;D
Polyphen
1.0
.;D;D
Vest4
0.32
MutPred
0.83
Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);Gain of solvent accessibility (P = 0.0584);
MVP
0.63
MPC
0.99
ClinPred
0.049
T
GERP RS
6.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.74
gMVP
0.89

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs145169006; hg19: chrX-119581776; API